21-36135345-G-C
Position:
Variant summary
Our verdict is Likely benign. Variant got -2 ACMG points: 2P and 4B. PM2BP4_Strong
The NM_001236.4(CBR3):āc.153G>Cā(p.Gln51His) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000275 in 1,612,594 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (ā ).
Frequency
Genomes: š 0.00030 ( 0 hom., cov: 34)
Exomes š: 0.00027 ( 0 hom. )
Consequence
CBR3
NM_001236.4 missense
NM_001236.4 missense
Scores
1
8
10
Clinical Significance
Conservation
PhyloP100: 2.88
Genes affected
CBR3 (HGNC:1549): (carbonyl reductase 3) Carbonyl reductase 3 catalyzes the reduction of a large number of biologically and pharmacologically active carbonyl compounds to their corresponding alcohols. The enzyme is classified as a monomeric NADPH-dependent oxidoreductase. CBR3 contains three exons spanning 11.2 kilobases and is closely linked to another carbonyl reductase gene - CBR1. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_benign. Variant got -2 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
BP4
Computational evidence support a benign effect (MetaRNN=0.013738275).
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CBR3 | NM_001236.4 | c.153G>C | p.Gln51His | missense_variant | 1/3 | ENST00000290354.6 | NP_001227.1 | |
CBR3-AS1 | NR_038893.1 | n.193-2271C>G | intron_variant, non_coding_transcript_variant | |||||
CBR3 | XM_011529772.3 | c.153G>C | p.Gln51His | missense_variant | 1/3 | XP_011528074.1 | ||
CBR3-AS1 | NR_038892.1 | n.193-1584C>G | intron_variant, non_coding_transcript_variant |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CBR3 | ENST00000290354.6 | c.153G>C | p.Gln51His | missense_variant | 1/3 | 1 | NM_001236.4 | ENSP00000290354 | P1 | |
CBR3-AS1 | ENST00000624080.1 | n.149-1872C>G | intron_variant, non_coding_transcript_variant | 5 |
Frequencies
GnomAD3 genomes AF: 0.000296 AC: 45AN: 152248Hom.: 0 Cov.: 34
GnomAD3 genomes
AF:
AC:
45
AN:
152248
Hom.:
Cov.:
34
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000452 AC: 111AN: 245642Hom.: 0 AF XY: 0.000478 AC XY: 64AN XY: 133940
GnomAD3 exomes
AF:
AC:
111
AN:
245642
Hom.:
AF XY:
AC XY:
64
AN XY:
133940
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000272 AC: 397AN: 1460228Hom.: 0 Cov.: 55 AF XY: 0.000277 AC XY: 201AN XY: 726452
GnomAD4 exome
AF:
AC:
397
AN:
1460228
Hom.:
Cov.:
55
AF XY:
AC XY:
201
AN XY:
726452
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000302 AC: 46AN: 152366Hom.: 0 Cov.: 34 AF XY: 0.000362 AC XY: 27AN XY: 74498
GnomAD4 genome
AF:
AC:
46
AN:
152366
Hom.:
Cov.:
34
AF XY:
AC XY:
27
AN XY:
74498
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ESP6500AA
AF:
AC:
0
ESP6500EA
AF:
AC:
2
ExAC
AF:
AC:
39
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Aug 12, 2021 | The c.153G>C (p.Q51H) alteration is located in exon 1 (coding exon 1) of the CBR3 gene. This alteration results from a G to C substitution at nucleotide position 153, causing the glutamine (Q) at amino acid position 51 to be replaced by a histidine (H). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Uncertain
DANN
Uncertain
DEOGEN2
Benign
T
Eigen
Uncertain
Eigen_PC
Uncertain
FATHMM_MKL
Benign
N
LIST_S2
Pathogenic
D
M_CAP
Benign
D
MetaRNN
Benign
T
MetaSVM
Uncertain
D
MutationAssessor
Benign
N
MutationTaster
Benign
D
PrimateAI
Uncertain
T
PROVEAN
Benign
N
REVEL
Uncertain
Sift
Uncertain
D
Sift4G
Uncertain
T
Polyphen
D
Vest4
MutPred
Loss of disorder (P = 0.1053);
MVP
MPC
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at